Improved Outcomes of Paediatric and Adult Crohn's Disease and Association With Emerging Use of Biologics–A Nationwide Study From the Epi-IIRN. (4th November 2021)
- Record Type:
- Journal Article
- Title:
- Improved Outcomes of Paediatric and Adult Crohn's Disease and Association With Emerging Use of Biologics–A Nationwide Study From the Epi-IIRN. (4th November 2021)
- Main Title:
- Improved Outcomes of Paediatric and Adult Crohn's Disease and Association With Emerging Use of Biologics–A Nationwide Study From the Epi-IIRN
- Authors:
- Atia, Ohad
Orlanski-Meyer, Esther
Lujan, Rona
Ledderman, Natan
Greenfeld, Shira
Kariv, Revital
Daher, Saleh
Yanai, Henit
Loewenberg Weisband, Yiska
Gabay, Hagit
Matz, Eran
Nevo, Daniel
Israeli, Eran
Schwartz, Doron
Chowers, Yehuda
Dotan, Iris
Turner, Dan - Abstract:
- Abstract: Background: The effectiveness of biologics for improving long-term outcomes in patients with Crohn's disease [CD] is still controversial. In this nationwide study, we aimed to evaluate trends of long-term outcomes in all CD patients in Israel during the biologics era. Methods: Trends of outcomes were analysed using data from the four Israeli health maintenance organisations, covering 98% of the population; joinpoint regression models were used to explore changes of these trends over 2005 to 2019. Results: A total of 16 936 patients were diagnosed with CD in Israel since 2005 (2932 [17%] paediatric onset, 14 004 [83%] adult onset) with 114 947 person-years of follow-up. The cumulative rate of any CD related surgery was 5%, 9%, 11%, and 14% at 1, 3, 5, and 10 years from diagnosis. The increase in use of biologics was sharp (from 8.9% to 36%; average annual percent change [AAPC], 14.3%), and the time to biologics was shorter in recent years (median time of 4.8 [1.9–8.1] years in those diagnosed in 2005–2008 compared with 0.5 [0.2–1.1] years in those diagnosed in 2015–2018; p < 0.001). A significant decrease was noted in the hazard of hospitalisations (1.3 [0.1–4.6] years compared with 0.2 [0.02–0.9] years; p < 0.001), steroid dependency (1.5 [0.2–5.4] years compared with 0.1 [0.02–0.4] years; p < 0.001), and intestinal surgeries [4.7 [1.6–8.2] years compared with 0.6 [0.2–1.4] years; p < 0.001), but not of perianal surgery (4.2 [1.1–7.7] years compared with 0.6Abstract: Background: The effectiveness of biologics for improving long-term outcomes in patients with Crohn's disease [CD] is still controversial. In this nationwide study, we aimed to evaluate trends of long-term outcomes in all CD patients in Israel during the biologics era. Methods: Trends of outcomes were analysed using data from the four Israeli health maintenance organisations, covering 98% of the population; joinpoint regression models were used to explore changes of these trends over 2005 to 2019. Results: A total of 16 936 patients were diagnosed with CD in Israel since 2005 (2932 [17%] paediatric onset, 14 004 [83%] adult onset) with 114 947 person-years of follow-up. The cumulative rate of any CD related surgery was 5%, 9%, 11%, and 14% at 1, 3, 5, and 10 years from diagnosis. The increase in use of biologics was sharp (from 8.9% to 36%; average annual percent change [AAPC], 14.3%), and the time to biologics was shorter in recent years (median time of 4.8 [1.9–8.1] years in those diagnosed in 2005–2008 compared with 0.5 [0.2–1.1] years in those diagnosed in 2015–2018; p < 0.001). A significant decrease was noted in the hazard of hospitalisations (1.3 [0.1–4.6] years compared with 0.2 [0.02–0.9] years; p < 0.001), steroid dependency (1.5 [0.2–5.4] years compared with 0.1 [0.02–0.4] years; p < 0.001), and intestinal surgeries [4.7 [1.6–8.2] years compared with 0.6 [0.2–1.4] years; p < 0.001), but not of perianal surgery (4.2 [1.1–7.7] years compared with 0.6 [0.2–1.4] years; p = 0.2). Outcomes were consistently worse in paediatric onset compared with adults. Conclusions: The rates of hospitalisations, steroid dependency, and intestinal resections decreased in association with increased use of biologics both in children and in adults, but not the rate of perianal surgeries. … (more)
- Is Part Of:
- Journal of Crohn's and colitis. Volume 16:Number 5(2022)
- Journal:
- Journal of Crohn's and colitis
- Issue:
- Volume 16:Number 5(2022)
- Issue Display:
- Volume 16, Issue 5 (2022)
- Year:
- 2022
- Volume:
- 16
- Issue:
- 5
- Issue Sort Value:
- 2022-0016-0005-0000
- Page Start:
- 778
- Page End:
- 785
- Publication Date:
- 2021-11-04
- Subjects:
- Crohn's disease -- biologics -- outcomes
Inflammatory bowel diseases -- Periodicals
616.344005 - Journal URLs:
- http://www.journals.elsevier.com/journal-of-crohns-and-colitis/ ↗
http://ecco-jcc.oxfordjournals.org/content/9/3 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1093/ecco-jcc/jjab204 ↗
- Languages:
- English
- ISSNs:
- 1873-9946
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4965.651500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22107.xml